Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis...
-
NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis...
-
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough ~ Statistically significant and clinically relevant improvements in patient reported outcomes in...
-
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough ~ Statistically significant and clinically relevant improvements in patient reported outcomes in...